NCT06546865

Brief Summary

Holmium laser enucleation of the prostate (HoLEP) is routinely performed with 24F, 26F, and 28F laser scopes. Proponents of larger caliber scopes suggest that the larger scope size allows for improved visualization, hemostasis, and operative efficiencies. Proponents of a smaller scope diameter suggest that by eliminating the need for pre-HoLEP urethral dilation to accommodate a larger scope. It has also been proposed that a smaller caliber scope is less traumatic to the urethra resulting in lower rates of bladder neck contracture and urethral stricture disease. Currently, to our knowledge, there are no level one evaluation examining scope size 22F versus 26F sheath in laser enucleation outcomes. The aim of our study is to determine if a smaller diameter scope is associated with improved laser enucleation time, post-operative recovery, rates of same-day discharge, or increasing intra-operative or postoperative complication rates

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
142

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Apr 2024

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 16, 2024

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

July 30, 2024

Completed
10 days until next milestone

First Posted

Study publicly available on registry

August 9, 2024

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 16, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 16, 2025

Completed
Last Updated

August 9, 2024

Status Verified

August 1, 2024

Enrollment Period

1 year

First QC Date

July 30, 2024

Last Update Submit

August 6, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Comparison of Operating Time

    Operating time as measured during the procedure measured in minutes.

    Intra-op

Secondary Outcomes (8)

  • Time to Catheter Removal

    Within 6 hours of procedure completion

  • Length of Hospital Stay

    Within 6 hours of procedure completion

  • Continence status

    One year post-procedure

  • International Prostate Symptom Score

    One year post-procedure

  • Quality of Life (QOL) as scored on the International Prostate Symptom Score (IPSS)

    One year post-procedure

  • +3 more secondary outcomes

Study Arms (2)

22F Sheath Size

ACTIVE COMPARATOR

Comparator arm for procedures using 22F sheath size

Device: 22F Sheath Size

26F Sheath Size

ACTIVE COMPARATOR

Comparator arm for procedures using 26F sheath size

Device: 26F Sheath Size

Interventions

Participants in this group will have the 22F sheath size used in their procedure.

22F Sheath Size

Participants in this group will have the 26F sheath size used in their procedure.

26F Sheath Size

Eligibility Criteria

Age50 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males over 50 years of age at the time of enrollment
  • Referred to urology for refractory LUTS secondary to BPH
  • Failed medical (non-surgical) treatment
  • Prostate size on preoperative TRUS of \> 80 ml
  • IPSS \>15, QOL score ≥3 and Qmax \<15 ml/sec
  • Written informed consent to participate in the study
  • Ability to comply with the requirements of the study procedures

You may not qualify if:

  • Previous surgical treatment for BPH
  • History of prostate cancer
  • Prostate size \< 80 mL
  • History of urethral stenosis or its management
  • Known or suspected neurogenic bladder
  • Participants with active urinary tract infection until appropriately treated
  • Participants with preexisting conditions, which, in the opinion of the investigator, interfere with the conduct of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Thunder Bay Regional Health Sciences Centre

Thunder Bay, Ontario, P7B 6V4, Canada

RECRUITING

MeSH Terms

Conditions

Prostatic Hyperplasia

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Study Officials

  • Hazem Elmansy

    Thunder Bay Regional Health Sciences Centre

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 30, 2024

First Posted

August 9, 2024

Study Start

April 16, 2024

Primary Completion

April 16, 2025

Study Completion

April 16, 2025

Last Updated

August 9, 2024

Record last verified: 2024-08

Data Sharing

IPD Sharing
Will not share

Locations